El Tai NO, El Fari M, Mauricio I, Miles MA, Oskam L, El Safi SH, Presber WH, Schönian G, 2001. Leishmania donovani: intraspecific polymorphisms of Sudanese isolates revealed by PCR-based analyses and DNA sequencing. Exp Parasitol 97: 35–44.
Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A, 1999. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 93: 319–323.
Sukmee T, Siripattanapipong S, Mungthin M, Worapong J, Rangsin R, Samung Y, Kongkaew W, Bumrungsana K, Chanachai K, Apiwathanasorn C, Rujirojindakul P, Wattanasri S, Ungchusak K, Leelayoova S, 2008. A suspected new species of Leishmania, the causative agent of visceral leishmaniasis in a Thai patient. Int J Parasitol 38: 617–622.
Bualert L, Charungkiattikul W, Thongsuksai P, Mungthin M, Siripattanapipong S, Khositnithikul R, Naaglor T, Ravel C, El Baidouri F, Leelayoova S, 2012. Autochthonous disseminated dermal and visceral leishmaniasis in an AIDS patient, southern Thailand, caused by Leishmania siamensis. Am J Trop Med Hyg 86: 821–824.
Chusri S, Hortiwakul T, Silpapojakul K, Siriyasatien P, 2012. Consecutive cutaneous and visceral leishmaniasis manifestations involving a novel Leishmania species in two HIV patients in Thailand. Am J Trop Med Hyg 87: 76–80.
Suankratay C, Suwanpimolkul G, Wilde H, Siriyasatien P, 2010. Autochthonous visceral leishmaniasis in a human immunodeficiency virus (HIV)-infected patient: the first in Thailand and review of the literature. Am J Trop Med Hyg 82: 4–8.
Lobsiger L, Muller N, Schweizer T, Frey CF, Wiederkehr D, Zumkehr B, Gottstein B, 2010. An autochthonous case of cutaneous bovine leishmaniasis in Switzerland. Vet Parasitol 169: 408–414.
Müller N, Welle M, Lobsiger L, Stoffel MH, Boghenbor KK, Hilbe M, Gottstein B, Frey CF, Geyer C, von Bomhard W, 2009. Occurrence of Leishmania sp. in cutaneous lesions of horses in Central Europe. Vet Parasitol 166: 346–351.
Reuss SM, Dunbar MD, Calderwood Mays MB, Owen JL, Mallicote MF, Archer LL, Wellehan JF Jr, 2012. Autochthonous Leishmania siamensis in horse, Florida, USA. Emerg Infect Dis 18: 1545–1547.
Paila YD, Saha B, Chattopadhyay A, 2010. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages. Biochem Biophys Res Commun 399: 429–433.
Sundar S, Rai M, 2005. Treatment of visceral leishmaniasis. Expert Opin Pharmacother 6: 2821–2829.
Rosenthal E, Marty P, Poizot-Martin I, Reynes J, Pratlong F, Lafeuillade A, Jaubert D, Boulat O, Dereure J, Gambarelli F, 1995. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg 89: 159–162.
Laguna F, 2003. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 97 (Suppl 1): 135–142.
Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M, 2009. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis 48: e16–e22.
Leelayoova S, Siripattanapipong S, Hitakarun A, Kato H, Tan-ariya P, Siriyasatien P, Osatakul S, Mungthin M, 2013. Multilocus characterization and phylogenetic analysis of Leishmania siamensis isolated from autochthonous visceral leishmaniasis cases, southern Thailand. BMC Microbiol 13: 60.
Murray HW, Berman JD, Davies CR, Saravia NG, 2005. Advances in leishmaniasis. Lancet 366: 1561–1577.
Cota GF, de Sousa MR, Rabello A, 2011. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis 5: e1153.
Molina I, Falcó V, Crespo M, Riera C, Ribera E, Curran A, Carrio J, Diaz M, Villar del Saz S, Fisa R, López-Chejade P, Ocaña I, Pahissa A, 2007. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 60: 837–842.
Berenguer J, Cosin J, Miralles P, Lopez JC, Padilla B, 2000. Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 14: 2946–2948.
López-Vélez R, Videla S, Márquez M, Boix V, Jiménez-Mejías ME, Górgolas M, Arribas JR, Salas A, Laguna F, Sust M, Cañavate C, Alvar J; Spanish HIV-Leishmania Study Group, 2004. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 53: 540–543.
Laguna F, 2003. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 97: 135–142.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||274||102||2|
We report the first case of visceral leishmaniasis caused by Leishmania siamensis in a seronegative child. She was treated with amphotericin B at 1 mg/kg/day for 3 weeks; however, recurrences occurred twice. The patient was cured after the administration of amphotericin B for 5 weeks and monthly prophylaxis for 6 months.
Financial support: This study was supported by Prince of Songkla University and Phramongkutklao College of Medicine.
Authors' addresses: Seksit Osatakul, Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand, E-mail: email@example.com. Mathirut Mungthin, Suradej Siripattanapipong, Atitaya Hitakarun, Rommanee Kositnitikul, Tawee Naaglor, and Saovanee Leelayoova, Department of Parasitology, Phramongkutklao College of Medicine, Bangkok 10400, Thailand, E-mails: firstname.lastname@example.org, email@example.com, firstname.lastname@example.org, email@example.com, Tawee_narkloar@hotmail.com, and firstname.lastname@example.org.